UNSPSC 51152301: Atropine/edrophonium

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AU300. This VA Drug Class (AU300) classifies this compound as belonging to the group PARASYMPATHOMIMETICS (CHOLINERGICS).

UNSPSC 51152301 Atropine/edrophonium is a Commodity code that in recent state and local practice encompasses procurement of pharmaceutical products and drug-related supplies for public health and emergency response. The recent opportunities tagged to this code show minimal direct relevance to atropine itself — the Seminole County solicitation centers on naloxone and drug deactivation systems, while the Texas HHS RFI addresses direct-to-manufacturer pharmacy prescription programs at scale. State and local health departments, county public health agencies, and state pharmacy benefit programs are the issuing bodies active under this code, though the actual scope of goods being solicited diverges substantially from the code's nominal pharmaceutical focus.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a statewide direct-to-manufacturer prescription program serving self-insured employer and state agency health plans. Activity under this code appears limited and geographically scattered across Florida and Texas, with no clear pattern of repeat buyers or sustained procurement volume. The code shows little recent activity aligned with its stated pharmaceutical scope, and the opportunities present do not establish this as an active category for traditional atropine or edrophonium procurement in state and local markets.